Season 2 (2021-2030)

Respiratory - Phase1 (1)

Modality Indication Targets Stage Company Project No. Detail
1 Phase I clinical study of SB17170 for the drug development for idiopathic pulmonary fibrosis
Small Molecules Idiopathic pulmonary fibrosis HMGB1 Phase 1 SPARK Biopharma RS-2023-00259223
BACK